Abstract 44P
Background
Oral cancer (OC) presents a high incidence of recurrences and metastasis. MicroRNA and sphingolipids alterations in plasma and tumors have been linked to many cancers. Sphingosine kinase 2 (SK2), which regulates sphingosine-1-phosphate levels, has been explored as a therapeutic target in cancer. Interestingly, our preliminary data indicate a correlation between SK2 and miRNA levels in OC. This study aimed to investigate miR-205 and miR-296, in the saliva of OC patients and the relationship between these miRNAs and SK2 in OC cells to elucidate further new diagnosis/prognosis and therapy strategies for oral cancer.
Methods
The saliva was collected and processed from 25 OC patients and 15 controls, followed by miRNA extraction. The survival rate of OC patients related to miRNA-205 and miRNA-296 levels in tumor samples was analyzed using the TCGA data. The salivary levels of the 2 miRNAs were determined by qRT-PCR. ROC curves were used to evaluate the potential of the miRNAs as biomarkers. OC cells (HN12 and HN13) without (control) and with SK2 overexpression (HN12-SK2) and SK2 knockdown (HN13-sh-SK2) were selected to evaluate the modulation of the miRNAs by qRT-PCR, as well as to perform migration and spheres assays after transfection with mimic-miRNA-205 and inhibitor for miRNA-296.
Results
The survival rate in OC patients was higher when the miR-205 was high and the miR-296 low. In our cohort, both miR-296 and miRNA-205 presented higher levels in the saliva of OC patients than in the controls. There was a positive correlation between tumor size and miR-296 levels in saliva, opposite to a negative correlation with miR-205. In vitro analysis showed that SK2 overexpression in HN12 cells (HN12-SK2) decreased the expression of miR-205 and increased miR-296, while the knockdown of SK2 in HN13 cells (HN13-sh-SK2) increased the miR-205 and decreased the miR-296. Besides, transfection of a miR-205 mimic and a miRNA-296 inhibitor in HN12/HN13 cells showed decreased cell migration and sphere formation.
Conclusions
We propose that the level of miR-205 and miR-296 in human saliva could be used for the diagnosis and prognosis of OC patients. Moreover, both miRNAs in OC cells may be regulated by sphingosine kinase 2 and explored as therapeutic targets in oral cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Academic Group.
Funding
Fundação de Amparo e Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract